Diffuse Parenchymal Lung Disease
7
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
14.3%
1 terminated out of 7 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Hydroxychloroquine (HCQ) in Pediatric Interstitial Lung Disease (ILD)
Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty
Ultra-Low Dose Computed Tomography For Diagnosis And Follow-Up Of Patients With Diffuse Parenchymal Lung Disease (DPLD)
Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF)
The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease
Race, Ethnicity, and Diffuse Parenchymal Lung Disease
Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease